WO2012028525A3 - Method for producing a tetranectin-apolipoprotein a-i particle, the lipid particle obtained therewith and its use - Google Patents

Method for producing a tetranectin-apolipoprotein a-i particle, the lipid particle obtained therewith and its use Download PDF

Info

Publication number
WO2012028525A3
WO2012028525A3 PCT/EP2011/064601 EP2011064601W WO2012028525A3 WO 2012028525 A3 WO2012028525 A3 WO 2012028525A3 EP 2011064601 W EP2011064601 W EP 2011064601W WO 2012028525 A3 WO2012028525 A3 WO 2012028525A3
Authority
WO
WIPO (PCT)
Prior art keywords
producing
apolipoprotein
particle
tetranectin
obtained therewith
Prior art date
Application number
PCT/EP2011/064601
Other languages
French (fr)
Other versions
WO2012028525A2 (en
Inventor
Martin Bader
Monika Baehner
Anton Jochner
Hubert Kettenberger
Silke Mohl
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to RU2013111676/15A priority Critical patent/RU2013111676A/en
Priority to EP11748407.1A priority patent/EP2611417A2/en
Priority to CN2011800387042A priority patent/CN103068369A/en
Priority to JP2013525305A priority patent/JP2013538205A/en
Priority to CA 2807441 priority patent/CA2807441A1/en
Priority to KR1020137005026A priority patent/KR20130117760A/en
Priority to BR112013004401A priority patent/BR112013004401A2/en
Priority to MX2013001539A priority patent/MX2013001539A/en
Publication of WO2012028525A2 publication Critical patent/WO2012028525A2/en
Publication of WO2012028525A3 publication Critical patent/WO2012028525A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

Herein is reported a method for producing a lipid particle comprising the following steps i) providing a first solution comprising denatured apolipoprotein, ii) adding the first solution to a second solution comprising at least two lipids and a detergent but no apolipoprotein, and iii) removing the detergent from the solution obtained in step ii) and thereby producing a lipid particle.
PCT/EP2011/064601 2010-08-30 2011-08-25 Method for producing a lipid particle, the lipid particle itself and its use WO2012028525A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
RU2013111676/15A RU2013111676A (en) 2010-08-30 2011-08-25 METHOD FOR PRODUCING TETRANEKTIN-APOLIPOPROTEIN A-I PARTICLES OBTAINED THROUGH THE LIPID PARTICLE AND ITS APPLICATION
EP11748407.1A EP2611417A2 (en) 2010-08-30 2011-08-25 Method for producing a tetranectin-apolipoprotein a-1 particle, the lipid particle obtained therewith and its use
CN2011800387042A CN103068369A (en) 2010-08-30 2011-08-25 Method for producing a lipid particle, the lipid particle itself and its use
JP2013525305A JP2013538205A (en) 2010-08-30 2011-08-25 Method for producing tetranectin-apolipoprotein AI particles, lipid particles obtained using the same, and uses thereof
CA 2807441 CA2807441A1 (en) 2010-08-30 2011-08-25 Method for producing a lipid particle, the lipid particle itself and its use
KR1020137005026A KR20130117760A (en) 2010-08-30 2011-08-25 Method for producing a tetranectin-apolipoprotein a-i particle, the lipid particle obtained therewith and its use
BR112013004401A BR112013004401A2 (en) 2010-08-30 2011-08-25 method for producing a lipid particle, the lipid particles themselves and their use.
MX2013001539A MX2013001539A (en) 2010-08-30 2011-08-25 Method for producing a tetranectin-apolipoprotein a-i particle, the lipid particle obtained therewith and its use.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10008994 2010-08-30
EP10008994.5 2010-08-30

Publications (2)

Publication Number Publication Date
WO2012028525A2 WO2012028525A2 (en) 2012-03-08
WO2012028525A3 true WO2012028525A3 (en) 2012-10-26

Family

ID=44509389

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/064601 WO2012028525A2 (en) 2010-08-30 2011-08-25 Method for producing a lipid particle, the lipid particle itself and its use

Country Status (9)

Country Link
EP (1) EP2611417A2 (en)
JP (1) JP2013538205A (en)
KR (1) KR20130117760A (en)
CN (1) CN103068369A (en)
BR (1) BR112013004401A2 (en)
CA (1) CA2807441A1 (en)
MX (1) MX2013001539A (en)
RU (1) RU2013111676A (en)
WO (1) WO2012028525A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6116565B2 (en) 2011-08-25 2017-04-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Cation and anion exchange chromatography
CN112546201A (en) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 Application of artificial lipoprotein particle apoA-IV fat body in treatment and/or prevention of diabetes

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608347A (en) * 1982-04-15 1986-08-26 Bernstam Victor A Compositions, uses and methods creating reverse micelles for the clarification of biological fluids to obtain undistorted assay of analytes following clarification
WO2005065708A2 (en) * 2003-12-30 2005-07-21 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
WO2006039622A2 (en) * 2004-10-01 2006-04-13 Invitrogen Corporation Feeding buffers, systems, and methods for in vitro synthesis of biomolecules
WO2006047614A2 (en) * 2004-10-26 2006-05-04 Invitrogen Corporation Compositions and methods for analyzing biomolecules using mass spectroscopy
WO2006069371A1 (en) * 2004-12-22 2006-06-29 Baylor College Of Medicine A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
WO2008013885A2 (en) * 2006-07-25 2008-01-31 Stratagene California Zwitterionic detergents for the storage and use of dna polymerases
WO2009097587A2 (en) * 2008-01-30 2009-08-06 The Rockefeller University Nanoscale bound bilayers, methods of use and production
US20090246859A1 (en) * 2003-03-12 2009-10-01 Qiagen North American Holdings, Inc. Methods and Compositions for Purification of Nucleic Acid from a Host Cell

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
US6291245B1 (en) 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
EP0972838B1 (en) 1998-07-15 2004-09-15 Roche Diagnostics GmbH Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy
AU2001253620A1 (en) 2000-04-14 2001-10-30 Nuvelo, Inc. Materials and methods relating to lipid metabolism
JP4344136B2 (en) * 2000-11-10 2009-10-14 エフ・ホフマン−ラ・ロシュ・リミテッド Apolipoprotein analog
EP1382614A1 (en) * 2002-07-15 2004-01-21 Bayer HealthCare AG Process for the purification of interleukin-4 and its muteins
CA2443365C (en) 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
EP1486571B1 (en) 2003-06-12 2005-12-14 F. Hoffmann-La Roche Ag Method for the recombinant production of polypeptides
PE20050438A1 (en) 2003-10-20 2005-06-14 Esperion Therapeutics Inc PHARMACEUTICAL FORMULAS, METHODS AND DOSING REGIMES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES
WO2005084642A1 (en) 2004-01-28 2005-09-15 Biodelivery Sciences International, Inc. Apoprotein cochleate compositions
EP1896074A4 (en) 2005-05-25 2009-04-22 Liponex Inc Pharmaceutical compositions for treating or preventing coronary artery disease
MX2008015337A (en) 2006-06-01 2009-11-26 Inst Cardiologie Montreal Method and compound for the treatment of valvular stenosis.
FR2915490B1 (en) * 2007-04-26 2011-10-28 Univ Joseph Fourier Grenoble I FORMATION OF PROTEOLIPOSOMES CONTAINING MEMBRANE PROTEINS USING A CELLULAR PROTEIN SYNTHESIS SYSTEM
JP2010539995A (en) * 2007-10-08 2010-12-24 アナフォア インコーポレイテッド Trimeric IL-1Ra
DK2288336T3 (en) 2008-04-25 2017-03-13 Univ Northwestern NANOSTRUCTURES SUITABLE FOR COMPLEXATION OF CHOLESTEROL

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608347A (en) * 1982-04-15 1986-08-26 Bernstam Victor A Compositions, uses and methods creating reverse micelles for the clarification of biological fluids to obtain undistorted assay of analytes following clarification
US20090246859A1 (en) * 2003-03-12 2009-10-01 Qiagen North American Holdings, Inc. Methods and Compositions for Purification of Nucleic Acid from a Host Cell
WO2005065708A2 (en) * 2003-12-30 2005-07-21 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
WO2006039622A2 (en) * 2004-10-01 2006-04-13 Invitrogen Corporation Feeding buffers, systems, and methods for in vitro synthesis of biomolecules
WO2006047614A2 (en) * 2004-10-26 2006-05-04 Invitrogen Corporation Compositions and methods for analyzing biomolecules using mass spectroscopy
WO2006069371A1 (en) * 2004-12-22 2006-06-29 Baylor College Of Medicine A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
WO2008013885A2 (en) * 2006-07-25 2008-01-31 Stratagene California Zwitterionic detergents for the storage and use of dna polymerases
WO2009097587A2 (en) * 2008-01-30 2009-08-06 The Rockefeller University Nanoscale bound bilayers, methods of use and production

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEVY D ET AL: "Reconstitution of the sarcoplasmic reticulum Ca<2+>-ATPase: mechanisms of membrane protein insertion into liposomes during reconstitution procedures involving the use of detergents", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 1107, no. 2, 30 June 1992 (1992-06-30), pages 283 - 298, XP027464334, ISSN: 0005-2736, [retrieved on 19920630], DOI: 10.1016/0005-2736(92)90415-I *

Also Published As

Publication number Publication date
RU2013111676A (en) 2014-10-10
MX2013001539A (en) 2013-03-18
BR112013004401A2 (en) 2016-05-17
CA2807441A1 (en) 2012-03-08
WO2012028525A2 (en) 2012-03-08
CN103068369A (en) 2013-04-24
JP2013538205A (en) 2013-10-10
KR20130117760A (en) 2013-10-28
EP2611417A2 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
WO2012028524A3 (en) Method for producing a tetranectin-apolipoprotein a-i lipid particle, the lipid particle itself and its use
WO2012123014A3 (en) A current limitation system for limiting the effects of a fault in a dc grid and a method of operating a current limitation system
WO2013158182A3 (en) Method of making a sandwich panel
WO2012014076A3 (en) Liver organoid, uses thereof and culture method for obtaining them
ZA201109191B (en) Mehtod for manufacturing composite connecting rods,and connecting rods produced according to the method
WO2011000879A3 (en) A method for producing a fermented milk product
WO2011031849A3 (en) Anionic lipids and lipid nanostructures and methods of producing and using same
WO2012085286A3 (en) A photovoltaic element
WO2013003297A3 (en) Stator core module, stator core assembly and process for assembling a stator core assembly
EP2647655A4 (en) High molecular compound, method for producing same, and light-emitting element
WO2012114122A3 (en) Construction panel
WO2013034616A3 (en) Capacitor component
EP2679826A4 (en) Impeller, rotor comprising same, and impeller manufacturing method
EP2433778A3 (en) Method for reducing differential shrinkage in stereolithography
WO2013106112A3 (en) Panel with core layer and method
WO2013096640A8 (en) Tessellation patterns
WO2013084160A3 (en) Graphene composite and a method of manufacturing a graphene composite
WO2011079920A3 (en) Method for producing a particle-based element
WO2011034551A3 (en) Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
WO2013030342A3 (en) Non-planar photovoltaic device
WO2011126604A3 (en) System and method for processing data
WO2012068323A3 (en) Method for matching of patterns
WO2012028525A3 (en) Method for producing a tetranectin-apolipoprotein a-i particle, the lipid particle obtained therewith and its use
WO2013092920A3 (en) Method of producing a resonator
EP2666975A4 (en) Turbine external compartment, frame for turbine external compartment, and method for constructing frame for turbine external compartment

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180038704.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11748407

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2011748407

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011748407

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2807441

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/001539

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2013525305

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20137005026

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013111676

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013004401

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013004401

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130225